Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.